Gengo Peter J, Pettit Hugh O, O'Neill Scott J, Wei Ke, McNutt Robert, Bishop Michael J, Chang Kwen-Jen
Ardent Pharmaceuticals, Inc., 631 United Dr., Suite 200, Durham, NC 27713, USA.
J Pharmacol Exp Ther. 2003 Dec;307(3):1221-6. doi: 10.1124/jpet.103.054361. Epub 2003 Oct 8.
Compound (+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), is one of a series of novel centrally acting agents with potent antinociceptive activity that binds specifically and with high affinity to opioid receptors. In saturation equilibrium binding studies performed at 25 degrees C using membranes from rat brain or guinea pig cerebellum, the Ki values measured for DPI-3290 at delta-, mu-, and kappa-opioid receptors were 0.18 +/- 0.02, 0.46 +/- 0.05, and 0.62 +/- 0.09 nM, respectively. In vas deferens isolated from laboratory mice, DPI-3290 decreased electrically induced tension development in a concentration-dependent manner with corresponding IC50 values of 1.0 +/- 0.3, 6.2 +/- 2.0, and 25.0 +/- 3.3 nM at delta-, mu-, and kappa-receptors, respectively. The activity of DPI-3290 in isolated vas deferens tissue was approximately 20,000, 175.8, and 1500 times more efficacious than morphine, and 492, 2.5, and 35 times more efficacious than fentanyl at delta-, mu-, and kappa-receptors, respectively. In ileal strips isolated from guinea pigs, DPI-3290 inhibited tension development with a corresponding IC50 value of 3.4 +/- 1.6 nM at mu-opioid receptors and 6.7 +/- 1.6 nM at kappa-opioid receptors. Intravenous administration of 0.05 +/- 0.007 mg/kg DPI-3290 produced a 50% antinociceptive response in rats. The antinociceptive properties of DPI-3290 were blocked by naloxone (0.5 mg/kg s.c.). Compared with morphine, this study demonstrated that DPI-3290 is more potent and elicited a similar magnitude of antinociceptive activity in the rat, actions mediated by its mixed opioid receptor agonist activity. The marked antinociceptive activity of DPI-3290 will likely provide a means for relieving severe pain in patients that require analgesic treatment.
化合物(+)-3-((α-R)-α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-羟基苄基)-N-(3-氟苯基)-N-甲基苯甲酰胺(DPI-3290)是一系列具有强效抗伤害感受活性的新型中枢作用药物之一,它能特异性且高亲和力地与阿片受体结合。在25℃下使用大鼠脑或豚鼠小脑的膜进行的饱和平衡结合研究中,DPI-3290在δ-、μ-和κ-阿片受体处测得的Ki值分别为0.18±0.02、0.46±0.05和0.62±0.09 nM。在从实验小鼠分离的输精管中,DPI-3290以浓度依赖性方式降低电诱导的张力发展,在δ-、μ-和κ-受体处的相应IC50值分别为1.0±0.3、6.2±2.0和25.0±3.3 nM。DPI-3290在分离的输精管组织中的活性在δ-、μ-和κ-受体处分别比吗啡有效约20,000、175.8和1500倍,比芬太尼有效492、2.5和35倍。在从豚鼠分离的回肠条中,DPI-3290在μ-阿片受体处抑制张力发展的相应IC50值为3.4±1.6 nM,在κ-阿片受体处为6.7±1.6 nM。静脉注射0.05±0.007 mg/kg DPI-3290在大鼠中产生50%的抗伤害感受反应。DPI-3290的抗伤害感受特性被纳洛酮(0.5 mg/kg皮下注射)阻断。与吗啡相比,本研究表明DPI-3290更有效,并且在大鼠中引发了相似程度的抗伤害感受活性,其作用由其混合阿片受体激动剂活性介导。DPI-3290显著的抗伤害感受活性可能为缓解需要镇痛治疗的患者的严重疼痛提供一种手段。